Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors

Pulmonary hypertension is a potentially fatal disease. Despite pharmacological advances in pulmonary hypertension, fatigue remains common in patients with pulmonary hypertension. A convenience sample of 120 participants at an international patient conference completed the Multidimensional Fatigue In...

Full description

Bibliographic Details
Main Authors: Todd M. Tartavoulle, Aryn C. Karpinski, Andrew Aubin, Benzi M. Kluger, Oliver Distler, Lesley Ann Saketkoo
Format: Article
Language:English
Published: European Respiratory Society 2018-03-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/4/1/00079-2017.full
id doaj-76e49f7cb00d411e9f7ec3945e456ed7
record_format Article
spelling doaj-76e49f7cb00d411e9f7ec3945e456ed72020-11-24T23:08:53ZengEuropean Respiratory SocietyERJ Open Research2312-05412018-03-014110.1183/23120541.00079-201700079-2017Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictorsTodd M. Tartavoulle0Aryn C. Karpinski1Andrew Aubin2Benzi M. Kluger3Oliver Distler4Lesley Ann Saketkoo5 School of Nursing, Louisiana State University Health Sciences Center – New Orleans, New Orleans, LA, USA Evaluation and Measurement, School of Foundations, Leadership and Administration, Kent State University, Kent, OH, USA School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA Dept of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA Dept of Rheumatology, University Hospital Zurich, Zurich, Switzerland New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, USA Pulmonary hypertension is a potentially fatal disease. Despite pharmacological advances in pulmonary hypertension, fatigue remains common in patients with pulmonary hypertension. A convenience sample of 120 participants at an international patient conference completed the Multidimensional Fatigue Inventory (MFI)-20 scale. Data on New York Heart Association Functional Class, body mass index, oxygen use and medication type/use were also collected. There was a high prevalence of “severe” to “very severe” fatigue for each dimension: General Fatigue (60%), Physical Fatigue (55.8%), Reduced Activity (41.7%), Reduced Motivation (32.5%) and Mental Fatigue (27.5%). The mean±sd overall MFI-20 score was 58±5.1. Dimensions with the highest averaged levels were General Fatigue (13.40±3.61), Physical Fatigue (13.23±3.67) and Reduced Activity (11.33±4.16). Body mass index correlated with higher fatigue scores. Phosphodiesterase inhibitor plus endothelin receptor antagonist combination negatively predicted General Fatigue, Physical Fatigue, Reduced Motivation and Reduced Activity. Triple therapy was a significant predictor of General Fatigue, Physical Fatigue and Reduced Activity. There were no significant predictors of Mental Fatigue. Multidimensional fatigue is common and severe in patients with pulmonary hypertension. Phosphodiesterase inhibitor plus endothelin receptor antagonist combination resulted in lower scores in most fatigue dimensions. Comprehensive assessment of fatigue should be considered in the clinical care of patients with pulmonary hypertension and clinical research to develop formal interventions that target this disabling symptom.http://openres.ersjournals.com/content/4/1/00079-2017.full
collection DOAJ
language English
format Article
sources DOAJ
author Todd M. Tartavoulle
Aryn C. Karpinski
Andrew Aubin
Benzi M. Kluger
Oliver Distler
Lesley Ann Saketkoo
spellingShingle Todd M. Tartavoulle
Aryn C. Karpinski
Andrew Aubin
Benzi M. Kluger
Oliver Distler
Lesley Ann Saketkoo
Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors
ERJ Open Research
author_facet Todd M. Tartavoulle
Aryn C. Karpinski
Andrew Aubin
Benzi M. Kluger
Oliver Distler
Lesley Ann Saketkoo
author_sort Todd M. Tartavoulle
title Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors
title_short Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors
title_full Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors
title_fullStr Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors
title_full_unstemmed Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors
title_sort multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors
publisher European Respiratory Society
series ERJ Open Research
issn 2312-0541
publishDate 2018-03-01
description Pulmonary hypertension is a potentially fatal disease. Despite pharmacological advances in pulmonary hypertension, fatigue remains common in patients with pulmonary hypertension. A convenience sample of 120 participants at an international patient conference completed the Multidimensional Fatigue Inventory (MFI)-20 scale. Data on New York Heart Association Functional Class, body mass index, oxygen use and medication type/use were also collected. There was a high prevalence of “severe” to “very severe” fatigue for each dimension: General Fatigue (60%), Physical Fatigue (55.8%), Reduced Activity (41.7%), Reduced Motivation (32.5%) and Mental Fatigue (27.5%). The mean±sd overall MFI-20 score was 58±5.1. Dimensions with the highest averaged levels were General Fatigue (13.40±3.61), Physical Fatigue (13.23±3.67) and Reduced Activity (11.33±4.16). Body mass index correlated with higher fatigue scores. Phosphodiesterase inhibitor plus endothelin receptor antagonist combination negatively predicted General Fatigue, Physical Fatigue, Reduced Motivation and Reduced Activity. Triple therapy was a significant predictor of General Fatigue, Physical Fatigue and Reduced Activity. There were no significant predictors of Mental Fatigue. Multidimensional fatigue is common and severe in patients with pulmonary hypertension. Phosphodiesterase inhibitor plus endothelin receptor antagonist combination resulted in lower scores in most fatigue dimensions. Comprehensive assessment of fatigue should be considered in the clinical care of patients with pulmonary hypertension and clinical research to develop formal interventions that target this disabling symptom.
url http://openres.ersjournals.com/content/4/1/00079-2017.full
work_keys_str_mv AT toddmtartavoulle multidimensionalfatigueinpulmonaryhypertensionprevalenceseverityandpredictors
AT arynckarpinski multidimensionalfatigueinpulmonaryhypertensionprevalenceseverityandpredictors
AT andrewaubin multidimensionalfatigueinpulmonaryhypertensionprevalenceseverityandpredictors
AT benzimkluger multidimensionalfatigueinpulmonaryhypertensionprevalenceseverityandpredictors
AT oliverdistler multidimensionalfatigueinpulmonaryhypertensionprevalenceseverityandpredictors
AT lesleyannsaketkoo multidimensionalfatigueinpulmonaryhypertensionprevalenceseverityandpredictors
_version_ 1725612536883052544